Foghorn Therapeutics Inc.
NASDAQ:FHTX
Income Statement
Earnings Waterfall
Foghorn Therapeutics Inc.
Income Statement
Foghorn Therapeutics Inc.
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
1
|
1
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
1
+67%
|
1
+39%
|
1
-14%
|
1
+53%
|
5
+275%
|
9
+85%
|
16
+72%
|
19
+22%
|
21
+7%
|
22
+5%
|
33
+50%
|
34
+5%
|
34
-1%
|
35
+4%
|
26
-27%
|
23
-11%
|
24
+4%
|
24
+3%
|
25
+1%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(69)
|
(79)
|
(87)
|
(95)
|
(102)
|
(112)
|
(122)
|
(130)
|
(136)
|
(143)
|
(147)
|
(147)
|
(142)
|
(137)
|
(130)
|
(127)
|
(123)
|
(121)
|
(116)
|
(111)
|
|
| Selling, General & Administrative |
(11)
|
(14)
|
(17)
|
(20)
|
(22)
|
(24)
|
(27)
|
(29)
|
(31)
|
(32)
|
(33)
|
(33)
|
(32)
|
(31)
|
(30)
|
(29)
|
(28)
|
(28)
|
(27)
|
(27)
|
|
| Research & Development |
(58)
|
(65)
|
(70)
|
(74)
|
(80)
|
(86)
|
(93)
|
(100)
|
(106)
|
(111)
|
(114)
|
(114)
|
(110)
|
(105)
|
(100)
|
(98)
|
(95)
|
(91)
|
(89)
|
(84)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
|
| Operating Income |
(69)
N/A
|
(78)
-14%
|
(86)
-10%
|
(94)
-9%
|
(101)
-8%
|
(107)
-6%
|
(113)
-6%
|
(115)
-2%
|
(117)
-2%
|
(123)
-5%
|
(126)
-2%
|
(114)
+9%
|
(108)
+6%
|
(103)
+5%
|
(95)
+8%
|
(102)
-7%
|
(100)
+1%
|
(97)
+3%
|
(92)
+6%
|
(87)
+6%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(0)
|
6
|
8
|
11
|
14
|
11
|
11
|
11
|
11
|
12
|
12
|
12
|
10
|
|
| Non-Reccuring Items |
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(2)
|
(2)
|
0
|
0
|
0
|
|
| Total Other Income |
1
|
2
|
2
|
3
|
3
|
3
|
4
|
6
|
3
|
2
|
1
|
(1)
|
3
|
3
|
3
|
3
|
4
|
5
|
5
|
4
|
|
| Pre-Tax Income |
(69)
N/A
|
(78)
-13%
|
(85)
-9%
|
(93)
-9%
|
(101)
-9%
|
(105)
-4%
|
(109)
-4%
|
(109)
+0%
|
(109)
+0%
|
(112)
-3%
|
(113)
-1%
|
(101)
+11%
|
(94)
+7%
|
(89)
+5%
|
(84)
+6%
|
(89)
-7%
|
(87)
+3%
|
(80)
+7%
|
(75)
+6%
|
(72)
+4%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(2)
|
(2)
|
(4)
|
(4)
|
(3)
|
(2)
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(69)
|
(78)
|
(85)
|
(93)
|
(101)
|
(105)
|
(109)
|
(109)
|
(109)
|
(112)
|
(115)
|
(103)
|
(98)
|
(93)
|
(86)
|
(91)
|
(87)
|
(80)
|
(75)
|
(72)
|
|
| Net Income (Common) |
(69)
N/A
|
(78)
-13%
|
(85)
-9%
|
(93)
-9%
|
(101)
-9%
|
(105)
-4%
|
(109)
-4%
|
(109)
+0%
|
(109)
+0%
|
(112)
-3%
|
(115)
-2%
|
(103)
+10%
|
(98)
+5%
|
(93)
+6%
|
(86)
+7%
|
(91)
-6%
|
(87)
+5%
|
(80)
+7%
|
(75)
+6%
|
(72)
+4%
|
|
| EPS (Diluted) |
-1.87
N/A
|
-2.11
-13%
|
-2.31
-9%
|
-2.51
-9%
|
-2.73
-9%
|
-2.54
+7%
|
-2.63
-4%
|
-2.61
+1%
|
-2.62
0%
|
-2.7
-3%
|
-2.75
-2%
|
-2.47
+10%
|
-2.34
+5%
|
-2.21
+6%
|
-1.67
+24%
|
-1.45
+13%
|
-1.58
-9%
|
-1.27
+20%
|
-1.2
+6%
|
-1.15
+4%
|
|